



INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Attorney Docket Number	4239-66902-01
Application Number	10/682,130
Filing Date	October 7, 2003
First Named Inventor	Klinman
Art Unit	1645
Examiner Name	Patricia Ann Duffy

U.S. PATENT DOCUMENTS

Copies of U.S. Patent documents do not need to be provided, unless requested by the Patent and Trademark Office. For patents, provide the patent number and the issue date. For published U.S. applications, provide the publication number and the publication date. For unpublished pending patent applications, provide the application number and the filing date.

Examiner's Initials*	Cite No. (optional)	Number	Publication Date	Name of Applicant or Patentee
NA		4,469,863	4 Sep 1984	Ts'o <i>et al.</i>
		5,023,243	11 June 1991	Tullis
		5,663,153	2 Sep 1997	Hutcherson <i>et al.</i>
		US-2004-0132682-A1	8 July 2004	Klinman <i>et al.</i>
		US-2004-0248834-A1	9 Dec 2004	Klinman <i>et al.</i>

FOREIGN PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Country	Number	Publication Date	Name of Applicant or Patentee
		EPC	EP 0 092 574	29 Apr 1992	Tullis
		WIPO/PCT	WO 83/01451	28 Apr 1983	Tullis
		WIPO/PCT	WO 95/26204	5 Sep 1995	Hutcherson <i>et al.</i>
		WIPO/PCT	WO 96/02555	1 Feb 1996	Krieg
		WIPO/PCT	WO 98/11211	19 Mar 1998	Agrawal
		WIPO/PCT	WO 98/18810	7 May 1998	Krieg <i>et al.</i>
		WIPO/PCT	WO 98/37919	3 Sep 1998	Schwartz <i>et al.</i>
		WIPO/PCT	WO 98/40100	17 Sep 1998	Davis <i>et al.</i>
↓		WIPO/PCT	WO 98/52581	26 Nov 1998	Davis <i>et al.</i>

EXAMINER SIGNATURE: /Nina Archie/	DATE CONSIDERED: 10/26/2006
-----------------------------------	-----------------------------

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Attorney Docket Number		4239-66902-01	
				Application Number		10/682,130	
				Filing Date		October 7, 2003	
				First Named Inventor		Klinman	
				Art Unit		1645	
				Examiner Name		Patricia Ann Duffy	
NA		WIPO/PCT	WO 99/51259	14 Oct 1999	Krieg <i>et al.</i>		
↓		WIPO/PCT	WO 03/027313	3 April 2003	Klinman <i>et al.</i>		
↓		WIPO/PCT	WO 2004/012669	12 Feb 2004	Klinman <i>et al.</i>		
Examiner's Initials*	Cite No. (optional)	OTHER DOCUMENTS					
NA		BATTEGAY, "Angiogenesis: mechanistic insights, neovascular diseases, and therapeutic prospects," <i>J. Molec. Med.</i> 73(7): 333-346, 1995					
↓		BECK <i>et al.</i> , "Vascular development: cellular and molecular regulation," <i>FASEB J.</i> 11(5): 365, 1997					
↓		BJERSING <i>et al.</i> , "Anti-proliferative effects of phosphodiester oligodeoxynucleotides," <i>Immunobiology</i> , 209(8):637-45, 2004					
↓		BRAUN <i>et al.</i> , "On the Difficulties of Establishing a Consensus on the Definition of and Diagnostic Investigations for Reactive Arthritis," <i>J. Rheumatol.</i> 27:2185-2192, 2000					
↓		BRITIGAN <i>et al.</i> , "Lactoferrin Binds CpG-Containing Oligonucleotides and Inhibits Their Immunostimulatory Effects on Human B Cells," <i>J. Immunol.</i> 167:2921-2928, 2001					
↓		CHEN <i>et al.</i> , "Identification of methylated CpG motifs as inhibitors of the immune stimulatory CpG motifs," <i>Gene Ther.</i> 8(13):1024-1032, 2001					
↓		DENG <i>et al.</i> , "Intra-articularly localized bacterial DNA containing CpG motifs induces arthritis," <i>Nat. Med.</i> 5:702-705, 1999					
↓		DENG <i>et al.</i> , "Synovial cytokine mRNA expression during arthritis triggered by CpG motifs of bacterial DNA," <i>Arthritis Res.</i> 3(1):48-53, 2001					
↓		DENG <i>et al.</i> , "The Features of Arthritis Induced by CpG Motifs in Bacterial DNA," <i>Arthritis Rheum.</i> 43:356-364, 2000					
↓		GAUDRIC <i>et al.</i> "Quantification of Angiogenesis due to Basic Fibroblast Growth Factor in a Modified Rabbit Corneal Model," <i>Ophthal. Res.</i> 24: 181, 1992					
↓		GURSEL <i>et al.</i> , "Sterically Stabilized Cationic Liposomes Improve the Uptake and Immunostimulatory Activity of CpG Oligonucleotides," <i>J. Immunol.</i> 167: 3324, 2001					
↓		GÜRSEL <i>et al.</i> , "Differential and competitive activation of human immune cells by distinct classes of CpG oligodeoxynucleotide," <i>J. Leuko.Biol.</i> 71:813-820, 2002					
↓		HAN <i>et al.</i> , "G-quadruplex DNA: a potential target for anti-cancer drug design," <i>Trends Pharmacol. Sci.</i> 21:136-142, 2000					
↓		HARTMANN <i>et al.</i> , "CpG DNA: A potent signal for growth, activation, and maturation of human dendritic cells," <i>Proc. Natl. Acad. Sci. USA</i> 96:9305-9310, 1999					
EXAMINER SIGNATURE: /Nina Archie/				DATE CONSIDERED: 10/26/2006			
* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.							

INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Attorney Docket Number	4239-66902-01
		Application Number	10/682,130
		Filing Date	October 7, 2003
		First Named Inventor	Klinman
		Art Unit	1645
		Examiner Name	Patricia Ann Duffy
NA		HO <i>et al.</i> , "An Immunomodulatory GpG Oligonucleotide for the Treatment of Autoimmunity via the Innate and Adaptive Immune Systems," <i>J. Immunol.</i> 171:4920-4926, 2003	
		KENYON <i>et al.</i> , "A Model of Angiogenesis in the Mouse Cornea," <i>Invest Ophthalmol. Vis. Sci.</i> 37:1625-1632, 1996	
		KLINMAN <i>et al.</i> , "CpG Motifs present in bacterial DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon γ ," <i>Proc. Natl. Acad. Sci. USA</i> 93:2879, 1996	
		KLINMAN <i>et al.</i> , "Contribution of CpG Motifs to the Immunogenicity of DNA Vaccines," <i>J. Immunol.</i> 158:3635-3639, 1997	
		KLINMAN <i>et al.</i> , "Activation of the innate immune system by CpG oligodeoxynucleotides: immunoprotective activity and safety," <i>Springer Semin. Immunopathol.</i> 22:173-183, 2000	
		KRIEG <i>et al.</i> , "CpG motifs in bacterial DNA trigger direct B-cell activation," <i>Nature</i> 374:546-549, 1995	
		KRIEG, "Commentary: A possible cause of joint destruction in septic arthritis," <i>Arthritis Research</i> 1(1):3-4, 1999	
		KRIEG, "From bugs to drugs: therapeutic immunomodulation with oligodeoxynucleotides containing CpG sequences from bacterial DNA," <i>Antisense Nucleic Acid Drug Dev</i> 11(3):181-188, 2001	
		KRIEG <i>et al.</i> , "Enhancing vaccines with immune stimulatory CpG DNA," <i>Curr Opin Mol Ther</i> 3(1):15-24, 2001	
		KRIEG, "From A to Z on CpG," <i>Trends Immunol.</i> 23(2):64-65, 2002	
		KRIEG, "CpG Motifs in bacterial DNA and their immune effects," <i>Annu Rev Immunol</i> 20:709-760, 2002	
		LENERT <i>et al.</i> , "CpG stimulation of primary mouse B cells is blocked by inhibitory oligodeoxyribonucleotides at a site proximal to NF-kappaB activation," <i>Antisense Nucleic Acid Drug Dev</i> 11(4):247-256, 2001	
		LIANG <i>et al.</i> , "Activation of Human B Cells by Phosphorothioate Oligodeoxynucleotides," <i>J. Clin. Invest.</i> 98:1119-1129, 1996	
		LICHTENBERG <i>et al.</i> , "The Rat Subcutaneous Air Sac Model: A Quantitative Assay of Antiangiogenesis in Induced Vessels," <i>Pharmacol Toxicol.</i> 84:34-40, 1999	
		MURCHIE <i>et al.</i> , "Tetraplex folding of telomere sequences and the inclusion of adenine bases," <i>EMBO J.</i> 13:993-1001, 1994	

EXAMINER SIGNATURE: / Nina Archie /	DATE CONSIDERED: 10/26/2006
* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Attorney Docket Number	4239-66902-01
		Application Number	10/682,130
		Filing Date	October 7, 2003
		First Named Inventor	Klinman
		Art Unit	1645
		Examiner Name	Patricia Ann Duffy
NA		PISETSKY <i>et al.</i> , "Immunological Properties of Bacterial DNA," <i>NY Acad. Sci.</i> 772:152-163, 1995	
		PISETSKY <i>et al.</i> , "Inhibition of Murine Macrophage IL-12 Production by Natural and Synthetic DNA," <i>Clin. Immunol.</i> 96, 198-204, 2000	
		QUARCOO <i>et al.</i> , "Inhibition of signal transducer and activator of transcription 1 attenuates allergen-induced airway inflammation and hyperreactivity," <i>J Allergy Clin Immunol.</i> , 114(2):288-95, 2004	
		ROMAN <i>et al.</i> , "Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants," <i>Nature Medicine</i> 3(8):849-854, 1997	
		STUNZ <i>et al.</i> , "Inhibitory oligonucleotides specifically block effects of stimulatory CpG oligonucleotides in B cells," <i>Eur J Immunol</i> 32(5):1212-1222, 2002	
		VERTHELYI <i>et al.</i> , "Human Peripheral Blood Cells Differentially Recognize and Respond to Two Distinct CpG Motifs," <i>J. Immunol.</i> 166:2372-2377, 2001	
		VIALAS <i>et al.</i> , "Oxidative Damage Generated by an Oxo-Metalloporphyrin onto the Human Telomeric Sequence," <i>Biochemistry</i> 39:9514-9522, 2000	
		WILTING <i>et al.</i> , "A modified chorioallantoic membrane (CAM) assay for qualitative and quantitative study of growth factors," <i>Anat. Embryol.</i> 183: 259-271, 1991	
		YAMADA <i>et al.</i> , "Effect of Suppressive DNA on CpG-Induced Immune Activation," <i>J. Immunol.</i> 169:5590-5594, 2002	
		YAMAMOTO <i>et al.</i> , "Unique Pallindromic Sequences in Synthetic Oligonucleotides are Required to Induce INF and Augment INF-Mediated Natural Killer Activity," <i>J. Immunol.</i> 148:4072-4076, 1992	
		YI <i>et al.</i> , "Rapid Immune Activation by CpG Motifs in Bacterial DNA," <i>J. Immun.</i> 157:5394-5402, 1996	
		ZEUNER <i>et al.</i> , "Reduction of CpG-induced arthritis by suppressive oligodeoxynucleotides," <i>Arthritis Rheum.</i> 46(8):2219-2224, 2002	
		ZHAO <i>et al.</i> , "Requirements for effective inhibition of immunostimulatory CpG motifs by neutralizing motifs," <i>Antisense Nucleic Acid Drug Dev.</i> 10(5):381-389, 2000	
		ZHENG <i>et al.</i> , "DNA containing CpG motifs induces angiogenesis," <i>PNAS</i> 99(13):8944-8949, 2002	

EXAMINER SIGNATURE:	/Nina Archie/	DATE CONSIDERED:	10/26/2006
* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.			